Cancer Family
Digestive System Neuroendocrine Neoplasm
CI-CAN-00000164Explore in graph →
Non-malignant76 active trials2 evidence items
- NCIt
- C27721
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000164Explore in graph →
Clinical trials
295 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04234568 | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | active not recruiting | Phase 1 | 31 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 18, 2026 |
| clinicaltrials |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | recruiting | Phase 1 | 104 | RayzeBio, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05687123 | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04609592 | Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | active not recruiting | Phase 1 | 10 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05262556 | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | completed | Phase 1 | 15 | Amr Mohamed MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07661420 | 211At-MABG in Adults With Advanced Neuroendocrine Cancers | not yet recruiting | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03879694 | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 1 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06663072 | Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 25 | University of ChicagoOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05610826 | Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver | withdrawn | Phase 1 / Phase 2 | 0 | University of ChicagoOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02021604 | Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma | recruiting | Phase 1 | 250 | Cook Children's Health Care SystemOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT02355535 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 | completed | Phase 1 | 48 | Vanquish Oncology, Inc.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02162446 | 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET | completed | Phase 1 / Phase 2 | 12 | IpsenINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT02685553 | Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00804336 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT02078843 | Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors(GaIN) | terminated | Phase 1 / Phase 2 | 54 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01548482 | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00942682 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01048892 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | completed | Phase 1 | 22 | Children's Oncology GroupNETWORK | 1 | Jan 30, 2014 | clinicaltrials |
Data updated 19 hours agoSource updated Sep 29, 2026source: clinicaltrials